M. Socinski
Molecular Biology · 2008–2019
A researcher in the Science corpus: 7 papers; trusts 3 researchers and is trusted by 10 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 17 citations into it
- Cancer Research — 12 citations into it
- Statistics and Probability — 6 citations into it; #4,781 of 12,932 by trust here, #3,801 by citations
Whom M. Socinski trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts M. Socinski overall
Papers from M. Socinski's perspective
Ordered by how strongly the researchers M. Socinski trusts endorse each paper. Same corpus, a different order for every researcher.
- Kernel-Based Reinforcement Learning
- Reinforcement learning design for cancer clinical trials
- Tree-Based Batch Mode Reinforcement Learning
- Adaptive Treatment of Epilepsy via Batch-mode Reinforcement Learning
- Optimal dynamic treatment regimes
- Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. (New England Journal of Medicine)
- Extremely randomized trees
- A Generalization Error for Q-Learning
- The Nature of Statistical Learning Theory
- Optimal Structural Nested Models for Optimal Sequential Decisions
Their papers
- Reinforcement Learning Strategies for Clinical Trials in Non-small Cell Lung Cancer (2011) — 219 citations
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs (2014) — 1,641 citations
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. (2019) — 822 citations
- Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC (2018) — 3,127 citations
- First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer (2017) — 1,383 citations
- Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. (2012) — 663 citations
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. (2008) — 1,292 citations